Home / WHO Europe HIV medication landscape
WHO Europe HIV Medication Access and Reimbursement Map
Explore the HIV medication landscape across 53 countries and areas of the WHO European Region, including Eastern Europe, the Caucasus and Central Asia. Choose a country to see every medicine, its status, and the source behind it.
Map
Share of verified records that are reimbursed. Select a country for medicine-level evidence.
Browse by country
| Country | Records | Reimbursed | Not reimbursed | Not available | Under review | Last checked |
|---|---|---|---|---|---|---|
| Albania | 38 | 6 | 15 | 3 | 14 | 14/09/2026 |
| Andorra | 38 | 20 | 2 | 2 | 14 | 14/09/2026 |
| Armenia | 38 | 5 | 0 | 19 | 14 | 14/09/2026 |
| Austria | 42 | 22 | 2 | 2 | 16 | 14/09/2026 |
| Azerbaijan | 38 | 5 | 0 | 21 | 12 | 14/09/2026 |
| Belarus | 38 | 5 | 3 | 18 | 12 | 14/09/2026 |
| Belgium | 42 | 29 | 1 | 2 | 10 | 02/11/2026 |
| Bosnia and Herzegovina | 38 | 6 | 15 | 3 | 14 | 14/09/2026 |
| Bulgaria | 42 | 19 | 3 | 2 | 18 | 14/09/2026 |
| Croatia | 42 | 23 | 3 | 2 | 14 | 02/11/2026 |
| Cyprus | 42 | 20 | 2 | 2 | 18 | 14/09/2026 |
| Czechia | 42 | 28 | 2 | 2 | 10 | 02/11/2026 |
| Denmark | 42 | 22 | 2 | 2 | 16 | 14/09/2026 |
| Estonia | 42 | 21 | 3 | 2 | 16 | 02/11/2026 |
| Finland | 42 | 22 | 2 | 2 | 16 | 14/09/2026 |
| France | 42 | 35 | 0 | 2 | 5 | 02/11/2026 |
| Georgia | 38 | 5 | 0 | 19 | 14 | 14/09/2026 |
| Germany | 42 | 24 | 0 | 2 | 16 | 14/09/2026 |
| Greece | 42 | 20 | 2 | 2 | 18 | 14/09/2026 |
| Hungary | 42 | 24 | 2 | 2 | 14 | 02/11/2026 |
| Iceland | 42 | 20 | 2 | 2 | 18 | 14/09/2026 |
| Ireland | 42 | 22 | 2 | 2 | 16 | 14/09/2026 |
| Israel | 38 | 22 | 0 | 2 | 14 | 14/09/2026 |
| Italy | 42 | 24 | 0 | 2 | 16 | 14/09/2026 |
| Kazakhstan | 38 | 5 | 0 | 21 | 12 | 14/09/2026 |
| Kyrgyzstan | 38 | 5 | 0 | 21 | 12 | 14/09/2026 |
| Latvia | 42 | 22 | 3 | 2 | 15 | 02/11/2026 |
| Lithuania | 42 | 19 | 3 | 2 | 18 | 14/09/2026 |
| Luxembourg | 42 | 20 | 2 | 2 | 18 | 14/09/2026 |
| Malta | 42 | 20 | 2 | 2 | 18 | 14/09/2026 |
| Monaco | 38 | 20 | 2 | 2 | 14 | 14/09/2026 |
| Montenegro | 38 | 6 | 15 | 3 | 14 | 14/09/2026 |
| Netherlands | 42 | 33 | 2 | 2 | 5 | 02/11/2026 |
| North Macedonia | 38 | 6 | 15 | 3 | 14 | 14/09/2026 |
| Norway | 42 | 22 | 2 | 2 | 16 | 02/11/2026 |
| Poland | 42 | 30 | 3 | 2 | 7 | 14/09/2026 |
| Portugal | 42 | 22 | 0 | 2 | 18 | 14/09/2026 |
| Republic of Moldova | 38 | 5 | 0 | 19 | 14 | 14/09/2026 |
| Romania | 42 | 19 | 3 | 2 | 18 | 14/09/2026 |
| Russian Federation | 38 | 5 | 3 | 18 | 12 | 14/09/2026 |
| San Marino | 38 | 20 | 2 | 2 | 14 | 14/09/2026 |
| Serbia | 38 | 6 | 15 | 3 | 14 | 14/09/2026 |
| Slovakia | 42 | 19 | 3 | 2 | 18 | 14/09/2026 |
| Slovenia | 42 | 19 | 3 | 2 | 18 | 14/09/2026 |
| Spain | 42 | 23 | 2 | 6 | 11 | 02/11/2026 |
| Sweden | 42 | 22 | 2 | 2 | 16 | 14/09/2026 |
| Switzerland | 38 | 28 | 2 | 2 | 6 | 02/11/2026 |
| Tajikistan | 38 | 5 | 0 | 21 | 12 | 14/09/2026 |
| Turkey | 38 | 18 | 3 | 5 | 12 | 14/09/2026 |
| Turkmenistan | 38 | 5 | 0 | 21 | 12 | 14/09/2026 |
| Ukraine | 38 | 5 | 0 | 19 | 14 | 14/09/2026 |
| United Kingdom | 38 | 25 | 1 | 2 | 10 | 02/11/2026 |
| Uzbekistan | 38 | 5 | 0 | 21 | 12 | 14/09/2026 |
How to read the data
Each record describes one medicine in one country or area. Marketing authorisation, national supply and reimbursement are separate measures; regional authorisation does not prove that a medicine is marketed, available or reimbursed in every country. Records under review are excluded from the reimbursed percentage and remain separately visible.
Status categories are an editorial comparison of the evidence stored for each country-product record. The database does not rank clinical quality, recommend treatment or infer national access from regional authorisation alone. Medicine availability, supply and reimbursement can change; records under review should not be read as confirmed access or non-access. This resource is for public information, research and policy discussion and is not prescribing guidance or medical advice.
If you identify an outdated record or can provide a current official source, please contact SHAPE so the database can be reviewed.